Mesothelioma Clinical Trials in the United States

Search Criteria:

Cancer Type/Condition: Mesothelioma
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active

1. Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2005_010, MK0683-014, NCT00128102
 

2. Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-14896, USFIRB#105715, AVF3483s, NCT00604461
 

3. Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBP08-01, NCT00700336
 

4. Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-063, NCT00165503
 

5. Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14203B, NCI-7103, 7103, NCT00309946
 

6. Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF3442S, NCT00295503
 

7. Phase II Study of Dasatinib in Patients With Previously Treated Malignant Mesothelioma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-30601, CALGB 30601, NCT00509041
 

8. An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TL139204, NCT00685204
 

9. Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-053, NCT00715611
 

10. An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MORAb-009-003, NCT00738582
 

11. Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Protocol - Final 2004-05-14, AAAA2861, NCT00859469
 

12. Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Protocol Amdt 6 dated 092508, AAAB9658, NCT00859495
 

13. Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects with Pulmonary and Pleural Malignancies

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0205, NCI-5270, 5270, NCT00041158
 

14. Phase I Study of FR901228 (Depsipeptide) and Flavopiridol in Patients With Advanced Primary Lung or Esophageal Cancer, Malignant Pleural Mesothelioma, or Lung or Pleural Metastases

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-05-C-0010, 5987, NCI-5987, NCT00098644
 

15. Gene Therapy for Pleural Malignancies

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 803776, UPCC 03505, NCT00299962
 

16. Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0288, NCT00402766
 

17. Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06C.549, NCT00437372
 

18. Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Phase: Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-1068, NCT00491855
 

19. A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181084, NCT00528619
 

20. Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Combination With Pemetrexed Disodium and Cisplatin in Patients With Unresectable Malignant Epithelial Pleural Mesothelioma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-08-C-0026, 08-C-0026, P07188, CAT-5001-1001, NCT00575770, 8210
 

21. Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAC3255, NCT00629343
 

22. Phase I Study of Sorafenib Tosylate, Pemetrexed Disodium, and Cisplatin in Patients With Advanced Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UMN-2007LS086, UMN-2007LS086, 0712M22703, BAYER-UMN-2007LS086, NCT00703638
 

23. Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-091, NCT00571298
 

24. Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0935, NCT00652574
 

25. Phase I Study of 1-methyl-d-tryptophan in Patients With Relapsed or Refractory Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: VU-VICC-PHI-0814, VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
 

26. Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study

Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HSC-2007-0109, NCT00585819

This information is current as of September 2009 and is from the National Cancer Institute's cancer information database.  See cancer.gov.